BAP1-wt (siRNA resistant)
(Plasmid
#108439)
-
PurposeStable expression of BAP1-wt in mammalian cells, gene has an introduced siRNA-resistance against siBAP1.
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 108439 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCI-puro
-
Backbone manufacturerDr. J. Mirkovitch, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland
- Backbone size w/o insert (bp) 5224
-
Vector typeMammalian Expression
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameBAP1
-
Alt nameUCHL2
-
Alt namehucep-6
-
Alt nameHUCEP-13
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2190
-
Mutationc.1641C>T, c.1644T>A, c.1647T>C, c.1650C>G, c.1653T>A
-
GenBank IDNM_004656.3
-
Entrez GeneBAP1 (a.k.a. HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2, hucep-6)
- Promoter CMV
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site NheI (not destroyed)
- 3′ cloning site EcoRI (not destroyed)
- 5′ sequencing primer T7 (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
BAP1-wt (siRNA resistant) was a gift from Emanuela Felley-Bosco & Rolf Stahel (Addgene plasmid # 108439 ; http://n2t.net/addgene:108439 ; RRID:Addgene_108439) -
For your References section:
Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition. Okonska A, Buhler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E. Mol Cancer Ther. 2019 Oct 16. pii: 1535-7163.MCT-19-0356. doi: 10.1158/1535-7163.MCT-19-0356. 10.1158/1535-7163.MCT-19-0356 PubMed 31619462